Simufilam

Simufilam
Clinical data
Other names	PTI-125, PTI-910
ATC code	None;
Pharmacokinetic data
Elimination half-life	4.5 hours
Identifiers
	IUPAC name 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one;
CAS Number	1224591-33-6;
PubChem CID	46195331;
UNII	6NV440YIO0;
KEGG	D12003;
ChEMBL	ChEMBL4650230;
Chemical and physical data
Formula	C15H21N3O
Molar mass	259.353 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC2(CC1)NCC(=O)N2Cc1ccccc1;
	InChI InChI=1S/C15H21N3O/c1-17-9-7-15(8-10-17)16-11-14(19)18(15)12-13-5-3-2-4-6-13/h2-6,16H,7-12H2,1H3; Key:BSQPTZYKCAULBH-UHFFFAOYSA-N;

Simufilam (PTI-125) is an experimental medication for the treatment of Alzheimer's disease that was being developed by the American pharmaceutical firm Cassava Sciences. Its development was discontinued in November 2024 after it failed to show clinical benefit during phase III clinical trials.